Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183040 · ClinicalTrials.gov registry record · Phase 2
HORMA: Hormonal Regulators of Muscle and Metabolism in Aging
A Phase 2 study of Frailty and Sarcopenia, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 2
- Study locations
NCT00183040 is a Phase 2 study of Frailty and Sarcopenia that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 108 participants, below the 1,504-participant average among 48 other Frailty trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00183040, a Phase 2 study of Frailty and Sarcopenia, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the relationship of deficiencies in testosterone and growth hormone to loss of muscle mass (sarcopenia) and functional impairment during aging and whether there is an interaction of these two hormone systems in maintaining normal skeletal muscle mass and physical function.
Conditions Studied
Interventions
- DRUG Recombinant human growth hormone
- DRUG Topical testosterone
Study Locations (2)
Massachusetts
- Tufts University - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2002-09 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183040
The ClinicalTrials.gov registry entry for NCT00183040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,504-participant average among 48 other Frailty trials with a reported enrollment target (93% lower). The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Frailty appearing as the primary indexed condition, and to 2 interventions - of which Recombinant human growth hormone is the first listed.
NCT00183040 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT00183040 about?
NCT00183040 is a clinical study titled "HORMA: Hormonal Regulators of Muscle and Metabolism in Aging". The purpose of this study is to determine the relationship of deficiencies in testosterone and growth hormone to loss of muscle mass (sarcopenia) and functional impairment during aging and whether there is an interaction of these two hormone systems in maintaining normal skeletal muscle mass and phy...
What is the current status of trial NCT00183040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2002-09. Estimated completion is 2007-02.
What conditions does trial NCT00183040 study?
This clinical trial studies the following conditions: Frailty, Sarcopenia, Muscle Weakness.
What interventions are being tested in trial NCT00183040?
The interventions under investigation include: Recombinant human growth hormone (DRUG), Topical testosterone (DRUG).
Who is sponsoring clinical trial NCT00183040?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00183040 being conducted?
This trial has 2 study locations across Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Frailty
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.